How does it work?

OvuSense is different from anything else you may have heard of, or used previously to monitor your fertility. That's because it measures core body temperature using a clinically proven vaginal sensor. The vaginal sensor is used overnight only, and data are downloaded to the dedicated OvuSense App each morning. OvuSense provides live updates predicting ovulation up to 24 hours in advance using your current cycle data, then confirming the date of ovulation, all in one device.

What are the benefits?

By providing core temperature data in real time, throughout each cycle, OvuSense solves the issues variable ovulation causes with monitoring fertility. Even if you have completely regular ovulation, the live prediction with a positive predictive value of 96% [a] and the 99% accurate ovulation confirmation [b] improve your chances of successful conception. OvuSense effectively combines the benefits of OPKs with the benefits of BBT measurement - with the convenience of monitoring in a single device. However, it is more accurate than both methods, going one step further by enabling clinical monitoring in conjunction with the tests offered by your doctor. OvuSense has been clinically proven in 8 key peer reviewed publications [c], [1], [2] which reported on 2 clinical trials and an ongoing epidemiological study. The OvuSense technology also has 10 granted patents [3]

What are the drawbacks?

OvuSense provides more accurate results by using a vaginal sensor. Some may find this less convenient than tracking using an external device, but many users report finding the routine of using OvuSense takes the hassle and guesswork out of understanding their cycles. The comfort and ease of use of the sensor was also published clinically [4].

[a] The positive predictive value measures how many of the predicted ovulations OvuSense gets right.

[b] The accuracy measures how many positive and absent ovulations OvuSense confirms correctly.

[c] Note: The majority of OvuSense publications are clinical posters shown at the annual meetings of the two largest clinical societies for reproductive medicine: ESHRE and ASRM. Poster publications are reviewed by a committee of peers for both societies and only allowed to be presented if deemed of sufficient scientific merit and robustness. They are then published as part of the proceedings of the meetings in the official society journals 'Human Reproduction' and 'Fertility and Sterility', respectively. As is the norm with the development of medical devices, the OvuSense trials were sponsored by the company but the primary authors of the posters are independent clinicians.

[1] The key publication outlining prediction of ovulation was shown at the 2014 ESHRE meeting: Papaioannou S, Delkos D, Pardey J (2014).
[2] The claims for accuracy are based on the data set shown in [1], originally published at the 2013 ASRM meeting as a quality index: Papaioannou S, Aslam M (2013).
[3] US Patents: US8684944, US8496597, US9155522, US9155523, US20190110692; European patents: EP1485690, EP2061380; Chinese patent: CN1650154.
[4] The comfort and ease of use of OvuSense were published in the Journal of Obstetrics and Gynecology in 2013, and this survey is repeated annually with our customers with continuous as good or better results: Papaioannou S, Aslam M (2013).